ICH Q5E - Comparability of Biotechnological/Biological Products

What it says

When a manufacturing process change is made to a biotechnological or biological product after initial licensure, a comparability exercise, combining analytical, and where necessary nonclinical or clinical data, must demonstrate that the change has not adversely affected the product's quality, safety or efficacy.

Paraphrased for plain-language clarity. Always verify against the current published regulation text.

What it means in practice

• Comparability assessments under this guideline are the mechanism that allows a biologics manufacturer to make necessary process improvements over a product's lifecycle without having to repeat a full clinical development program for every change.
• The depth of comparability data required scales with the risk of the change, a minor analytical method change requires far less than a change to the cell substrate or manufacturing site, connecting this guideline closely to the risk-based thinking in ICH Q9(R1).
• Comparability findings depend heavily on having well-characterized, validated analytical methods capable of actually detecting a meaningful difference between pre-change and post-change product, tying this guideline to ICH Q6A and Q6B.

What inspectors look for

• Whether manufacturing process changes were assessed for their potential impact on product comparability before being implemented, with the depth of assessment matched to the change's risk.
• Whether the analytical methods used to support a comparability conclusion are sensitive enough to detect meaningful differences, not just broadly similar results.
• Whether comparability data adequately covers all quality attributes that could plausibly be affected by the specific change made.

Related regulations